

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

**INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF
HANG SENG COMPOSITE INDEX**

The board of directors (the “**Board**”) of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, according to the results of the quarterly review of the Hang Seng Family of Indexes for the period ended 30 June 2026 announced by Hang Seng Indexes Company Limited on 21 August 2026, the Company has been selected and will be included as a constituent stock of the Hang Seng Composite Index (“**HSCI**”), with effect from 7 September 2026.

Following its inclusion as a constituent stock of the HSCI, the Company’s H shares are expected to meet the eligibility criteria for inclusion under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are channels for stock trading and investment between capital market investors in Hong Kong and Chinese Mainland.

The Board believes that the inclusion in the HSCI reflects the capital market’s recognition of the Company’s value and growth potential, which will help broaden the Company’s shareholder base and increase the trading liquidity of its H shares. For further details, please refer to the relevant index notice(s) published on the website of Hang Seng Indexes Company Limited (<https://www.hsi.com.hk>).

The Board appreciates the continued support from the shareholders and investors of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 24 August 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.